MicroRNA-133a acts as a tumour suppressor in breast cancer through targeting LASP1

Abstract

Many microRNAs (miRs) have been demonstrated to play promoting or tumor suppressive roles in human cancers including breast cancer. However, the molecular mechanism of miR-133a underlying the malignant progression of breast cancer still remains obscure. In the present study we observed that the expression of miR-133a was significantly downregulated in breast cancer tissues and cell lines, when compared with adjacent non-tumor tissues and normal breast cell line, respectively. Reduced miR-133a levels were significantly associated with advanced clinical stage, lymph node metastasis, as well as shorter survival time of patients with breast cancer. Restoration of miR-133a expression led to significant decrease in the proliferation, migration, and invasion of SK-BR-3 and MDA-MB-231 cells in vitro, as well as in tumor xenograft growth in nude mice. Luciferase reporter gene assay data identified LASP1 as a target gene of miR-133a, and the expression of LASP1 was negatively regulated by miR-133a in breast cancer cells. LASP1 was significantly upregulated in breast cancer tissues and cell lines, and its upregulation was significantly associated with disease progression. siRNA-induced LASP1 downregulation caused a significant reduction in breast cancer cell proliferation, migration and invasion. Furthermore, overexpression of LASP1 impaired the suppressive effects of miR-133a upregulation on the proliferation, migration and invasion of SK-BR-3 and MDA-MB-231 cells. In summary, the present study demonstrates that miR-133a acts as a tumor suppressor in breast cancer partly at least via targeting LASP1, and thus suggests that the miR-133a/LASP1 axis may become a potential therapeutic target for breast cancer.

MicroRNA-511 inhibits malignant behaviors of breast cancer by directly targeting SOX9 and regulating the PI3K/Akt pathway

“…The dysregulation of miRNAs is involved in the tumorigenesis and progression of breast cancer due to their negative regulation of downstream target genes (35)(36)(37). It is generally accepted that miRNAs may have tumor-suppressive or oncogenic roles in breast cancer and participate in the regulation of numerous cellular biological processes (16,38,39). Notably, development of effective computational models for the prediction of potential breast cancer-associated miRNAs has been a research hot spot in recent years (40)(41)(42)(43)(44)(45).…”

Aberrant expression of a five‐microRNA signature in breast carcinoma as a promising biomarker for diagnosis

“…Studies which held by Wu et al demonstrated that low expression of miR‐133a was correlated with the poor survival of BC patients and restoration of miR‐133a expression inhibited BC cell growth and invasion. Sui et al also confirmed these findings, and they reported that miR‐133a levels were significantly decreased in BC patients which is associated with high levels of the malignancy, lymph node metastasis, and shorter survival time of the patients. Although miR‐133a has been reported to be a tumor suppressor and down‐regulated in several cancer types, Shen et al observed an up‐regulation of circulating miR‐133a in BC patients.…”

Key microRNAs in the biology of breast cancer; emerging evidence in the last decade

“…Convincing evidence has demonstrated the significant roles of miRNAs in several physiological activities, like organ development, cell growth, differentiation, and apoptosis, as well as in the incidence of various types of tumors (Cheng, Byrom, Shelton, & Ford, ; Goldar, Khaniani, Derakhshan, & Baradaran, ). In cancer, miRNAs can also function either as tumor suppressors or oncogenes (oncomiRs) in tumor progression and metastasis (Serpico, Molino, & Di Cosimo, ; Sui, Zhang, Yang, Wei, & Wang, ). Moreover, both metastamiRs (prometastatic) and metastasis‐suppressor (antimetastatic) miRNAs are very important in the metastatic mechanisms of tumors (Baffa et al, ).…”